Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516531 | 0.84 | PSMB8 (0.33) | MGLLKMT2AATM | |
| SCHEMBL14095230 | 0.83 | LMNA (0.32) | MGLLKMT2AATM | |
| SCHEMBL2618714 | 0.82 | MGLL (0.34) | MGLLKMT2AATM | |
| SCHEMBL12884880 | 0.81 | KMT2A (0.33) | SLC1A2MGLLKMT2AGAA | |
| SCHEMBL12884882 | 0.81 | SMN1; SMN2 (0.36) | MGLLKMT2AGAA | |
| SCHEMBL12884887 | 0.80 | SMN1; SMN2 (0.38) | KMT2AGAA | |
| SCHEMBL12884889 | 0.80 | SMN1; SMN2 (0.38) | KMT2AGAA | |
| SCHEMBL6033533 | 0.79 | MGAM (0.43) | MGLLKMT2AATMGAAGLA | |
| SCHEMBL13183261 | 0.79 | BRD4 (0.39) | MGLLKMT2AATMGAAGLA | |
| SCHEMBL18395365 | 0.78 | SLC1A2 (0.35) | SLC1A2MGLLKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-9878066-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170049924-A1 | CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES | HYPERBRANCH MEDICAL TECHNOLOGY, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20160263238-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9393344-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9289512-B2 | Maytansinoid derivatives with peptide linker and conjugates thereof | IMMUNOGEN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20130029900-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20100069927-A1 | Polymeric Masking Materials for Spanning Wound Sites, and Methods of Use Thereof | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | SLC1A2 1046/4885MGLL 2420/4885KMT2A 751/4885 |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, PLOD2, PLOD1 | SLC1A2 1119/4885MGLL 3215/4885KMT2A 1057/4885 |
| US-20160263238-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | VIP, HDGF, NGLY1 | SLC1A2 633/4885MGLL 4850/4885KMT2A 3960/4885 |
| US-20130029900-A1 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF | VIP, HDGF, NGLY1 | SLC1A2 633/4885MGLL 4850/4885KMT2A 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.